Cargando…

Copeptin, pro-atrial natriuretic peptide and pro-adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnea—a prospective intervention study

STUDY OBJECTIVES: Obstructive sleep apnea (OSA) might lead to oxidative stress, inflammation and elevated circulating copeptin, proANP and proADM levels. We aimed to evaluate whether the levels of these prohormones are higher in patients with OSA and whether they might change under continuous positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Karakioulaki, Meropi, Grendelmeier, Peter, Strobel, Werner, Schmid, Thomas, Jahn, Kathleen, Grize, Leticia, Tamm, Michael, Stolz, Daiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059312/
https://www.ncbi.nlm.nih.gov/pubmed/33879148
http://dx.doi.org/10.1186/s12931-021-01704-0
_version_ 1783681176006819840
author Karakioulaki, Meropi
Grendelmeier, Peter
Strobel, Werner
Schmid, Thomas
Jahn, Kathleen
Grize, Leticia
Tamm, Michael
Stolz, Daiana
author_facet Karakioulaki, Meropi
Grendelmeier, Peter
Strobel, Werner
Schmid, Thomas
Jahn, Kathleen
Grize, Leticia
Tamm, Michael
Stolz, Daiana
author_sort Karakioulaki, Meropi
collection PubMed
description STUDY OBJECTIVES: Obstructive sleep apnea (OSA) might lead to oxidative stress, inflammation and elevated circulating copeptin, proANP and proADM levels. We aimed to evaluate whether the levels of these prohormones are higher in patients with OSA and whether they might change under continuous positive airway pressure (CPAP) therapy, serving as potential proxies for the diagnosis and therapy-response in OSA. METHODS: A total of 310 patients with suspicion of OSA were recruited. Screening for OSA was performed using overnight pulse oximetry followed by polygraphy and a venous puncture in the morning. All patients diagnosed with OSA underwent CPAP adaptation. A venous puncture was conducted in the night before CPAP and in the following morning. At 1 and 6 months of treatment, polygraphy was performed, followed by a venous puncture in the morning. In the acquired blood, copeptin, proANP and proADM levels were measured. RESULTS: We analyzed 232 patients with OSA and 30 patients without OSA. Our results indicated that only copeptin levels differed significantly among patients with and without OSA at baseline. In OSA patients, the levels of proADM significantly changed after 1 and 6 months on CPAP therapy, when compared to baseline (p < 0.001 and p = 0.020). Additionally, proANP levels significantly decreased after 12 h on CPAP therapy, as compared to baseline levels (p < 0.001). CONCLUSIONS: Copeptin is significantly associated with the presence of OSA. ProANP levels might serve as a potential proxy for the acute response to non-invasive ventilation (12 h), while proADM reflects the long-term response (1 and 6 months). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-021-01704-0.
format Online
Article
Text
id pubmed-8059312
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80593122021-04-21 Copeptin, pro-atrial natriuretic peptide and pro-adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnea—a prospective intervention study Karakioulaki, Meropi Grendelmeier, Peter Strobel, Werner Schmid, Thomas Jahn, Kathleen Grize, Leticia Tamm, Michael Stolz, Daiana Respir Res Research STUDY OBJECTIVES: Obstructive sleep apnea (OSA) might lead to oxidative stress, inflammation and elevated circulating copeptin, proANP and proADM levels. We aimed to evaluate whether the levels of these prohormones are higher in patients with OSA and whether they might change under continuous positive airway pressure (CPAP) therapy, serving as potential proxies for the diagnosis and therapy-response in OSA. METHODS: A total of 310 patients with suspicion of OSA were recruited. Screening for OSA was performed using overnight pulse oximetry followed by polygraphy and a venous puncture in the morning. All patients diagnosed with OSA underwent CPAP adaptation. A venous puncture was conducted in the night before CPAP and in the following morning. At 1 and 6 months of treatment, polygraphy was performed, followed by a venous puncture in the morning. In the acquired blood, copeptin, proANP and proADM levels were measured. RESULTS: We analyzed 232 patients with OSA and 30 patients without OSA. Our results indicated that only copeptin levels differed significantly among patients with and without OSA at baseline. In OSA patients, the levels of proADM significantly changed after 1 and 6 months on CPAP therapy, when compared to baseline (p < 0.001 and p = 0.020). Additionally, proANP levels significantly decreased after 12 h on CPAP therapy, as compared to baseline levels (p < 0.001). CONCLUSIONS: Copeptin is significantly associated with the presence of OSA. ProANP levels might serve as a potential proxy for the acute response to non-invasive ventilation (12 h), while proADM reflects the long-term response (1 and 6 months). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-021-01704-0. BioMed Central 2021-04-20 2021 /pmc/articles/PMC8059312/ /pubmed/33879148 http://dx.doi.org/10.1186/s12931-021-01704-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Karakioulaki, Meropi
Grendelmeier, Peter
Strobel, Werner
Schmid, Thomas
Jahn, Kathleen
Grize, Leticia
Tamm, Michael
Stolz, Daiana
Copeptin, pro-atrial natriuretic peptide and pro-adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnea—a prospective intervention study
title Copeptin, pro-atrial natriuretic peptide and pro-adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnea—a prospective intervention study
title_full Copeptin, pro-atrial natriuretic peptide and pro-adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnea—a prospective intervention study
title_fullStr Copeptin, pro-atrial natriuretic peptide and pro-adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnea—a prospective intervention study
title_full_unstemmed Copeptin, pro-atrial natriuretic peptide and pro-adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnea—a prospective intervention study
title_short Copeptin, pro-atrial natriuretic peptide and pro-adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnea—a prospective intervention study
title_sort copeptin, pro-atrial natriuretic peptide and pro-adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnea—a prospective intervention study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059312/
https://www.ncbi.nlm.nih.gov/pubmed/33879148
http://dx.doi.org/10.1186/s12931-021-01704-0
work_keys_str_mv AT karakioulakimeropi copeptinproatrialnatriureticpeptideandproadrenomedullinasmarkersofhypoxicstressinpatientswithobstructivesleepapneaaprospectiveinterventionstudy
AT grendelmeierpeter copeptinproatrialnatriureticpeptideandproadrenomedullinasmarkersofhypoxicstressinpatientswithobstructivesleepapneaaprospectiveinterventionstudy
AT strobelwerner copeptinproatrialnatriureticpeptideandproadrenomedullinasmarkersofhypoxicstressinpatientswithobstructivesleepapneaaprospectiveinterventionstudy
AT schmidthomas copeptinproatrialnatriureticpeptideandproadrenomedullinasmarkersofhypoxicstressinpatientswithobstructivesleepapneaaprospectiveinterventionstudy
AT jahnkathleen copeptinproatrialnatriureticpeptideandproadrenomedullinasmarkersofhypoxicstressinpatientswithobstructivesleepapneaaprospectiveinterventionstudy
AT grizeleticia copeptinproatrialnatriureticpeptideandproadrenomedullinasmarkersofhypoxicstressinpatientswithobstructivesleepapneaaprospectiveinterventionstudy
AT tammmichael copeptinproatrialnatriureticpeptideandproadrenomedullinasmarkersofhypoxicstressinpatientswithobstructivesleepapneaaprospectiveinterventionstudy
AT stolzdaiana copeptinproatrialnatriureticpeptideandproadrenomedullinasmarkersofhypoxicstressinpatientswithobstructivesleepapneaaprospectiveinterventionstudy